Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OT: Apply to become an astronaut
Must like long road trips and Pampers for adults
http://news.yahoo.com/s/space/20070918/sc_space/nasabeginshuntfornewastronauts
"We need a tax code that's fair — a tax code that rewards work and advances opportunity," Obama said in a speech to the Tax Policy Center."
It is self-explanatory what's wrong with this statement.
>i may have bought some of your shares at 4.84<
If you were a day trader, you would be very happy right now.
HTE
Can someone advance a rational explanation why HTE would fall on a day like today. Given that oil is at, what, $81, and HTE's yield is in the 15%+ range?
Not to mention the payout ratio is in the low 60's, so there's little risk for a dividend cut. If anything, the dividend could increase.
"Barack Obama will unveil a new tax plan today, which will propose more than $80 billion in annual tax relief for workers and seniors funded by an increase on wealthier investors. According to an AP report, Obama “wants to give 150 million working Americans a $500 tax credit, expand relief for homeowners, eliminate income taxes for seniors making less than $50,000 and simplify tax returns so millions of Americans can file in less than five minutes.”
Anyone want to guess the income level at which one transitions from a "worker" to "wealthier"? Somehow I think none of that tax relief is coming my way.
If I'm lucky, maybe they'll push my total tax burden up above 50% of my income! It's almost there already.
Half a point. Ridiculous.
Is it just me, or is this completely unsound policy? Seems like a gift to Wall Street, as well as the heavily indebted.
>CSE, nice buying opportunity today.<
This has to go down in history as the best idea I've gotten from a message board. Thank you--although I don't get the dividend this quarter, I'm up 16% and the effective yield is 15%.
E*Trade Warns of Mortgage Fallout
Via DD on Biotech Values
*****************************************
[The company, which many people didn’t know was even in the mortgage business, plans to take $345M in write-offs for bad loans and impaired mortgage-backed securities. Imagine how many $7.99 commissions it will take to recoup the $345M!]
http://online.wsj.com/article/SB119006126061630102.html
>>
By SUSANNE CRAIG
September 17, 2007 5:15 p.m.
E*Trade Financial Corp., best known for providing cheap trades to individual investors, this afternoon warned investors that it has been badly stung by the recent fallout in the mortgage market.
The company says it expects profits to come in 31% below the most recent guidance it had given analysts -- partly due to its exposure to the mortgage business.
The news, weeks ahead of its scheduled third-quarter earnings report, provided Wall Street with a glimpse of what may be in store tomorrow when the country's biggest brokerages, beginning with Lehman Brothers Holdings Inc., start reporting third quarter earnings. After years of blowout profits, traders are bracing for a rough quarter as firms like Lehman grapple with the effects rising mortgage defaults have had on their business. Wall Street firms, including E*Trade, have many tentacles in this business.
For E*Trade, which is scheduled to release earnings in mid-October, the pain is significant. It warned it will earn approximately $1.10 a share this year, down about 31% from the $1.60 or so it was forecasting.
"We want to get this issue behind us and put the focus solely back on our core retail customer," E*Trade Chief Executive Officer Mitch Caplan said in an interview. He stressed that despite the recent issues, the company does not have a liquidity problem and released detailed information about its current financial picture along with today's announcement.
While most people associate E*Trade with online trading, the mortgage business was a big driver of E*Trade's earnings growth over the past few years. E*Trade, a buyer of mortgages from third parties, plans to get out of that business altogether and has set aside $245 million, up from $70 million, to cover related losses over the next four quarters. This provision will cover both losses on mortgages the company has made and bought from third parties as well as home-equity lines, a trouble spot for E*Trade. The firm says that as of the end of August, 2% of its $17-billion mortgage portfolio was comprised of delinquent loans while 2.8% of its $12.6 billion home equity portfolio is at increased risk.
In addition, the firm says that it may need to take a charge of up to $100 million to cover losses in its $18 billion-plus securities portfolio, which includes assets backed by mortgages that are now worth less than they were a few months ago.
As part of the sweeping package of financial charges announced this afternoon, the firm said it plans to spend more time focusing on its retail customer base and will restructure its balance sheet so it is more reliant on cash and assets it generates from customers on everything from margin loans to E*Trade originated home loans. Specifically, it hopes that as much as 85% of its balance sheet will be driven by customer related activity, up from about 60% today. As a result, E*Trade said investors should expect to see $18 million less in earnings over the next four quarters.
It will cost E*Trade $32 million in expenses just to exit that one mortgage business and overhaul another unrelated business that provides services to big or institutional clients.
The news could also cast a cloud over the merger discussions it was having with rival TD Ameritrade Holding Corp. The two sides had been recently been discussing whether to merge operations, according to people familiar with the matter. Yesterday's announcement will no doubt raise short-term concerns Ameritrade executives have expressed concern about E*Trade's reliance on the mortgage business.
<<
The Big List of High-Yield Investments
This list does not constitute an endorsement, nor do I know anything about 80% of these stocks. It is simply a list of high-yielding stocks and funds either found by me or suggested by participants.
Please feel free to add and repost. Yield information is current as of Sept 10, 2007
No new additions since last week, but I removed Boulder Growth and Income fund. Although this is mostly an unedited list, I consider BIF a *big fat* scam. The principals of this fund must have cajones grandes.
http://biz.yahoo.com/ts/070511/10356250.html?.v=1
Speaking of which: if there is anything else on here that would be irresponsible to continue including, please let me know and I will consider removing.
AAV
ADVANTAGE ENERGY FD 14.70%
ABR
ARBOR REALTY TR 12.90%
ACAS
AMER CAP STRATEGIE 9.20%
ADVDX
ALPINE DYNAMIC DIVIDEND FUND 14.0%
AGD
ALPINE GLOBAL DYNAMI 9.10%
AHT
ASHFORD HOSP TR INC 8.00%
AINV
APOLLO INVESTMENT CO 9.30%
AOD
ALPINE TOTAL DYNAMIC Around 9.0%
APL
ATLAS PIPELINE PTNRS 7.30%
APU
AMERIGAS PARTNERS LP 9.60%
ARCC
ARES CAPITAL CORP 10.30%
AWP
ALPINE GBL PRMR PROP Around 9.0%
BEP
S&P 500 CVRD CALL FD 11.40%
BFK
BLACKROCK MUN INC TR 6.20% (tax advantaged)
BGF
B&G FOODS INC. EIS Around 8.5%
BKCC
BLACKROCK KELSO CAPI 11.60%
BKN
BLACKROCK INV MUNI 6.00%
BNY
BLACKROCK NY MUN INC 5.50% (tax advantaged)
BPT
B P PRUDHOE BAY UTS 11.00%
BRT
B R T REALTY TRUST 12.10%
BSD
BLACKROCK ST MUNI TR 6.20% (tax advantaged)
BTE
BAYTEX ENERGY TR UTS 11.40%
BVF
BIOVAIL CORP 8.60%
CHI
CALAMOS CV OPP & INC 10.30%
CNE
CANETIC RESOURCES TR 15.10%
CPL
CPFL ENERGIA SA ADS 10.00%
CSE
CAPITALSOURCE INC 13.70%
CVP
CENTERPLATE INC IDS N/A
DCA
DIV CAP RTY INC FD 11.50%
DMLP
DORCHESTER MINLS 9.20%
DMLP
DORCHESTER MINLS 9.20%
DOM
DOMINION RES WARR TR 13.50%
DSX
DIANA SHIPPING INC. 7.30%
EBI
EVGRN INTL BAL INCM 8.30%
EDD
MORGAN STANLEY EMDD Around 10.0%
EGLE
EAGLE BULK SHIPPING 7.00%
EOD
EVGRN GBL DIV OPP FD Around 10.0%
EOS
EATON VANCE ENH EQ 9.10%
ERF
ENERPLUS RES FD 11.00%
ERH
EVERGREEN UTILITIES 10.00%
FHI
1ST TR STR HI INC FD 12.30%
FRO
FRONTLINE LTD 13.20%
HCD
HIGHLAND DIST OP INC 8.7%
HQH
H Q HEALTHCARE SBI 8.50%
HQL
HQ LIFE SCIENCES IND 8.50%
HTE
HARVEST ENERGY TRUST 15.90%
HYB
NEW AMER HIG INCM FD 10.60%
JDD
NUVEEN DI DIV & INC 9.30%
JGT
NUVEEN MUL-CUR ST GV <10.0%
JLA
NUVEEN EQ PRM ADV FD 10.00%
JSN
NUVEEN EQ PREM OP FD 9.90%
KMR
KINDER MORGAN MNGMNT 7.10%
MFD
MACQUARIE FIRST GLBL 11.90%
MTR
MESA ROYALTY TR 11.80%
NCV
NICHOLASAPPLGT CV IN 10.20%
NCZ
NICHOLAS -APP CONV & 9.80%
NRI
NEUBERGER BRMN RLTY 12.20%
NRO
NB RE SECS INC FD 12.00%
PFN
PIMCO FL RT STGY FND 9.90%
PGH
PENGROWTH EGY UTS 16.40%
PHF
PACHOLDER HI YLD FD 10.00%
PHK
PIMCO HIGH INCOME FD 9.90%
PHT
PIONEER HIGH INC TR 9.80%
RDR
RMR PFD DIVIDEND FD 12.10%
SFL
SHIP FINC INTL 7.90%
SJT
SAN JUAN BASIN ROYAL 9.30%
TRMD
AKTIESELSKABET DAM 13.10%
USS
US SHIPPING PARTNERS 9.50%
VRTB
VESTIN REALTY MORTGA 11.20%
>I would have thought that we have the opposite problem, that given the intellect required to become a doctor and practice medicine, at some point at the margin students smart enough to go to medical school will go work for Goldman Sachs or a hedge fund.<
This is a very good point. Becoming a doctor is a long, arduous process that not only involves medical school but years of low-paid, high-stress labor before you start making a reasonable income.
Although not a direct analogy, I went to grad school at Columbia. We started with about 15 people in the molecular biology program, and 3 got their PhDs. What happened to most of the rest? Wall Street or high-paid consulting jobs.
This issue might be less exaggerated outside of New York City; nevertheless if you're smart enough to go to grad school (or medical school) you've got options. Cut the pay of doctors and you'll also cut the number of talented physicians dramatically.
Just from experience--since a good half of my friends are in medicine--people don't become doctors for the big payout at the end. There are plenty of easier ways to make money if you've got the brains to get into med school.
This makes me ill. We're going to rescue the over-spenders and over-reachers by mortgaging our economy.
I think Bernanke is beholden to Bush for appointing him. Even though lowering interest rates is probably the worst possible move for the economy long-term, it seems the current administration is more concerned with shunting all of its problems (including, but hardly limited to, the economy) to the next administration rather than stepping up to the plate now.
I often get the feeling that Bush's strategy is to screw things up so thoroughly that there's no chance the next administration will be able to set things straight without some major, major pain. And we all know that whoever is in office gets blamed, regardless of whether they had anything to do with it or not.
I guess all of this doesn't matter to me much. I'll still make money: A dive in the dollar means I make more on my ex-US investments. Lower interest rates also mean that equity investments with yield become relatively more attractive, opening up the potential for some excellent returns beyond the dividend income.
>8. Don't even think about being funny or using flowery language. Science writing is a puritanical, serious, and reputable business, so any efforts to come up with creative names for genes or species should be suppressed.<
There is *nothing* more irritating than a scientific/medical paper written by someone who thinks he/she is a Writer (with a capital W).
They're just getting us back for RAAS, RANTES, and GM-CSF.
Thanks Jonathan. It sounds like HYB is a pretty terrible investment with this in mind. Like buying a Canroy with a payout ratio of >100%.
>As such, some might question the validity of this study, particularly in comparison to double-blind, placebo-controlled trials<
And what I need is more stock.
Nice day for Canroys, thanks to $80 oil.
I would not be surprised if many of these companies raise their dividends. HTE's payout ratio is currently 67% even with last quarter's (relatively) lower oil prices. If they maintain the same payout ratio, dividends should go up.
I think I know what this is saying, but I'll probably make a fool of myself if I try to explain. So I have to defer to someone with more expertise than myself....sorry.
Would love to hear an expert's take, if any are out there.
RPRX
Um, I don't think anyone on the RPRX board expected a phase III trial for Proellex in endometriosis. They were just trying to rationalize why the stock is being dumped today on reasonably good news.
OT: $80 oil today
Remember all those stories last year about how the high price of gas was hurting the average American? Where did they go?
Time for a good, hard recession. I feel sorry for whoever gets elected in 2008.
$80 oil.
Anyone who thinks inflation is "under control" is crazy.
Time for a recession.
It is a little odd to see JAV swing 5% on no news and minimal volume. It's hard to watch.
As someone else said, it's probably the result of some day trader in his basement.
This should be an 8.00+ stock, even before the UK approval. The fact that small-timers can push JAV up and down to the extent they are doing is a little tragic.
BVF
I know about the lawsuit, but traffic accidents?
VRUS
After a nice day yesterday, and decent volume, volume in VRUS is headed back into the toilet. 65,000 shares traded today. Needless to say, I think I'm going to be forced into an LTR with this company.
BVF
Not that I care about TheStreet.com's ratings, but for what it's worth...
Don't mind me...just talking to myself.
Biovail (BVF - Cramer's Take - Stockpickr - Rating) engages in the clinical testing, registration, manufacture and commercialization of pharmaceutical products using various drug-delivery technologies. It has been downgraded to a hold from a buy. The company has some strengths and some weaknesses. It has no debt to speak of, profit margins are expanding and it has a quick ratio of 2.10, demonstrating its ability to cover short-term liquidity needs.
As a counter to these strengths, Biovail EPS growth has been feeble, its return on equity has been disappointing and its net income fell 20.5% in the second quarter compared to the same period last year. The stock's price has increased by 13.81% in the past 12 months, despite the company's weak earnings. There is currently no conclusive evidence that warrants the purchase or sale of this stock. Biovail had been rated a buy since December 2006.
BVF
What has management lied about, specifically?
Realtors Predict Drop in 2007 Home Sales
Tuesday September 11, 6:32 pm ET
By Alan Zibel, AP Business Writer
Realtors Group Foresees 8.6 Percent Drop in Existing Home Sales in 2007
Consider the source.
WASHINGTON (AP) -- A trade group for real estate agents on Tuesday lowered its forecast 2007 existing home sales for the seventh-straight month, predicting a drop of 8.6 percent from last year.
The National Association of Realtors' revised monthly prediction calls for U.S. existing home sales of 5.9 million in 2007, down from 6.5 million last year. The forecast was below last month's prediction of a 6.8 percent drop.
This year's sales would be the lowest since 2002, when sales hit 5.6 million. Home sale prices this year are forecast to drop 1.7 percent to a median of $218,200.
Next year, the trade group expects existing home sales to climb to 6.3 million. It forecasts new home sales will fall 24 percent to 801,000 this year and 741,000 next year.
The forecast comes as delinquencies among borrowers with weak, or subprime, credit have risen dramatically over the past year, and other loans are showing weakness as well.
Lawrence Yun, NAR's senior economist, said lower sales are related to the ongoing problems in the mortgage market for people with weak credit and a lack of funding for jumbo home loans above $417,000.
Those loans can't be packaged into securities sold to investors by government-sponsored mortgage giants Fannie Mae and Freddie Mac. Lenders have been charging higher rates for these loans because they are not backed by Fannie or Freddie.
The real estate trade group described a big cutback in the construction of new homes as a "healthy trend" that will reduce inventory. The group projected construction of new homes will fall to 1.4 million this year from 1.8 million last year.
Last week, the NAR said pending sales of existing homes fell in July to the lowest level in nearly six years as borrowers struggled to finalize home purchases, particularly in expensive areas.
Investors around the world have been spooked by the U.S. mortgage market's problems, amid uncertainty about how much they will grow. The Federal Deposit Insurance Corp. estimates that 2.5 million mortgages given to borrowers with weak credit will reset at higher rates and sometimes dramatically higher monthly payments by the end of next year.
The number of homeowners receiving foreclosure notices hit a record high in the spring, driven up by problems with subprime mortgages and heavy job losses in Ohio and other Midwest states.
Oil Hits New Record on Supply Concerns
Tuesday September 11, 6:25 pm ET
By John Wilen, AP Business Writer
Oil Hits Record on Supply Concerns As Investors Look Past OPEC's Decision to Boost Production
Good for Canroys, MLPs, etc.
Whatever happened to all the stories about how awful high gasoline prices are for the average American?
NEW YORK (AP) -- Oil prices rose to a new record settlement price Tuesday as traders turned their attention to a government inventory report expected to show tight supplies and shrugged off OPEC's decision to boost output.
Even factoring in OPEC's decision to increase oil production by 500,000 barrels per day starting Nov. 1, "supplies are tight," said Addison Armstrong, an analyst at TFS Energy Futures LLC.
And according to analyst predictions, they're going to get even tighter. Analysts surveyed by Dow Jones Newswires, on average, expect Wednesday's report from the Energy Department's Energy Information Administration will say that crude oil inventories fell by 2.7 million barrels in the week ended Sept. 7.
Investors had already priced in OPEC's increase, and many were looking for a larger production boost, analysts said.
Light, sweet crude for October delivery rose 74 cents to settle at $78.23 a barrel on the New York Mercantile Exchange after alternating frequently between gains and losses. The settlement price bested the previous record, set July 31, by 2 cents.
Oil's rise pulled October gasoline 0.25 cent higher to settle at $1.9811 a gallon after the contract spent much of the day in negative territory. In other Nymex trading, heating oil futures rose 1.11 cents to settle at $2.1827 a gallon, and October natural gas added 4.3 cents to settle at $5.934 per 1,000 cubic feet.
In London, October Brent crude rose 90 cents to settle at $76.38 a barrel on the ICE Futures exchange.
OPEC, which produces about 40 percent of the world's oil, had long been expected to hold production levels steady at the meeting. But rumors started circulating on Monday that Saudi Arabia was campaigning to boost production.
Many analysts think the Saudis are worried high oil prices will crimp demand for crude, which could hurt OPEC nations in the long run.
However, some analysts interpreted the fact that Tuesday's meeting lasted longer than expected as a sign the Saudis had a hard time persuading other OPEC nations to boost production. Tim Evans, an analyst at Citigroup Inc., thinks some OPEC members are worried demand for oil will slow in the fourth quarter, which combined with more supplies could mean sharply lower prices.
Many OPEC countries already produce more oil than their quotas. But Omar Farouk Ibrahim, spokesman for the Organization of Petroleum Exporting Countries, said the announced increase would be based on the group's current production, not quotas -- meaning the 12-nation cartel will be adding actual oil to the market.
That translates into a quota increase of nearly 1.4 million barrels per day, Evans said.
"This is a big number," Evans said, adding that it would take futures traders a while to digest its significance. "This is not something that the market's going to adjust to in a few minutes."
At the pump, meanwhile, gas prices slid 0.5 cent overnight to a national average of $2.814 a gallon, according to AAA and the Oil Price Information Service. Retail prices, which typically lag the futures market, peaked at $3.227 in late May.
Analysts expect the EIA report will show gasoline inventories fell by 500,000 barrels last week, while refinery utilization fell by 0.1 percentage points to 92 percent of capacity. Inventories of distillates, which include heating oil and diesel fuel, rose by 1.4 million barrels.
Traders are also awaiting a report Wednesday from the International Energy Agency projecting oil demand for the fourth quarter.
"There's going to be a lot for energy traders to chew on here," said Evans.
>You specifically stated in 2 posts that JAV's pps isn't going anywhere due to UK approval, and 2. they won't make any money in the EU with Dyloject.<
Agree with Thomas. Dyloject is perhaps the world's easiest sell in the context of a heavily regulated, cost-sensitive market.
The key to selling in such an environment is to demonstrate value. The ability to skip the pharmacy and go straight to the patient is huge, as is the ability to cut down on bed time and personnel costs associated with infusion.
These are all clear-cut advantages for anyone trying to save money. The fact that Dyloject is better tolerated and perhaps slightly more efficacious than current options in Europe is just dressing. Nice to have, but not critical for penny-pinchers.
DrBio's posts on JAV have been ridiculous.
BVF
As some of you know, I started a high-yield board elsewhere on I-Hub. BVF just caught my attention as it was mentioned in a newsletter as yielding 8.7%. Other than getting the dividend right, the newsletter article was filled with all sorts of fun inaccuracies. But hey what can you expect from a non-biotech specialist.
Now I know nobody answers these kinds of questions, but anyone have any strong feelings about this company? I'm just watching for now, given the volatility in the market, and the fact that the Fed isn't going to cut rates, I think there is plenty of time to wait for a bargain. In fact, I suspended my 20-week plan for a few weeks.
The Big List of High-Yield Investments
This list does not constitute an endorsement, nor do I know anything about 80% of these stocks. It is simply a list of high-yielding stocks and funds either found by me or suggested by participants.
Please feel free to add and repost. Yield information is current as of Sept 10, 2007
Most notable new addition (in my opinion): Biovail (BVF). Finally, something a simple lad like me can understand! The only question is do I put it in my biotech portfolio or in my high-yield portfolio?
All stocks posted as Symbol Name Yield
AAV
ADVANTAGE ENERGY FD 14.70%
ABR
ARBOR REALTY TR 12.90%
ACAS
AMER CAP STRATEGIE 9.20%
ADVDX
ALPINE DYNAMIC DIVIDEND FUND 14.0%
AGD
ALPINE GLOBAL DYNAMI 9.10%
AHT
ASHFORD HOSP TR INC 8.00%
AINV
APOLLO INVESTMENT CO 9.30%
AOD
ALPINE TOTAL DYNAMIC Around 9.0%
APL
ATLAS PIPELINE PTNRS 7.30%
APU
AMERIGAS PARTNERS LP 9.60%
ARCC
ARES CAPITAL CORP 10.30%
AWP
ALPINE GBL PRMR PROP Around 9.0%
BEP
S&P 500 CVRD CALL FD 11.40%
BFK
BLACKROCK MUN INC TR 6.20% (tax advantaged)
BGF
B&G FOODS INC. EIS Around 8.5%
BIF
BOULDER GR & INC FD 13.90%
BKCC
BLACKROCK KELSO CAPI 11.60%
BKN
BLACKROCK INV MUNI 6.00%
BNY
BLACKROCK NY MUN INC 5.50% (tax advantaged)
BPT
B P PRUDHOE BAY UTS 11.00%
BRT
B R T REALTY TRUST 12.10%
BSD
BLACKROCK ST MUNI TR 6.20% (tax advantaged)
BTE
BAYTEX ENERGY TR UTS 11.40%
BVF
BIOVAIL CORP 8.60%
CHI
CALAMOS CV OPP & INC 10.30%
CNE
CANETIC RESOURCES TR 15.10%
CPL
CPFL ENERGIA SA ADS 10.00%
CSE
CAPITALSOURCE INC 13.70%
CVP
CENTERPLATE INC IDS N/A
DCA
DIV CAP RTY INC FD 11.50%
DMLP
DORCHESTER MINLS 9.20%
DMLP
DORCHESTER MINLS 9.20%
DOM
DOMINION RES WARR TR 13.50%
DSX
DIANA SHIPPING INC. 7.30%
EBI
EVGRN INTL BAL INCM 8.30%
EDD
MORGAN STANLEY EMDD Around 10.0%
EGLE
EAGLE BULK SHIPPING 7.00%
EOD
EVGRN GBL DIV OPP FD Around 10.0%
EOS
EATON VANCE ENH EQ 9.10%
ERF
ENERPLUS RES FD 11.00%
ERH
EVERGREEN UTILITIES 10.00%
FHI
1ST TR STR HI INC FD 12.30%
FRO
FRONTLINE LTD 13.20%
HCD
HIGHLAND DIST OP INC 8.7%
HQH
H Q HEALTHCARE SBI 8.50%
HQL
HQ LIFE SCIENCES IND 8.50%
HTE
HARVEST ENERGY TRUST 15.90%
HYB
NEW AMER HIG INCM FD 10.60%
JDD
NUVEEN DI DIV & INC 9.30%
JGT
NUVEEN MUL-CUR ST GV <10.0%
JLA
NUVEEN EQ PRM ADV FD 10.00%
JSN
NUVEEN EQ PREM OP FD 9.90%
KMR
KINDER MORGAN MNGMNT 7.10%
MFD
MACQUARIE FIRST GLBL 11.90%
MTR
MESA ROYALTY TR 11.80%
NCV
NICHOLASAPPLGT CV IN 10.20%
NCZ
NICHOLAS -APP CONV & 9.80%
NRI
NEUBERGER BRMN RLTY 12.20%
NRO
NB RE SECS INC FD 12.00%
PFN
PIMCO FL RT STGY FND 9.90%
PGH
PENGROWTH EGY UTS 16.40%
PHF
PACHOLDER HI YLD FD 10.00%
PHK
PIMCO HIGH INCOME FD 9.90%
PHT
PIONEER HIGH INC TR 9.80%
RDR
RMR PFD DIVIDEND FD 12.10%
SFL
SHIP FINC INTL 7.90%
SJT
SAN JUAN BASIN ROYAL 9.30%
TRMD
AKTIESELSKABET DAM 13.10%
USS
US SHIPPING PARTNERS 9.50%
VRTB
VESTIN REALTY MORTGA 11.20%
IMM
Woohoo! This just made a long, long day of teleconferences so much brighter. I love a man in uniform.
No I do not own this. I just thought it was ridiculous.
General Wesley Clark Joins Immtech as Consulting Strategic Advisor
Monday September 10, 9:02 am ET
NEW YORK, Sept. 10 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM - News) is pleased to announce today that General Wesley Clark (ret.) has joined Immtech as a strategic advisor. General Clark will provide counsel to Immtech's management team as the Company develops its drug programs targeting various global health challenges, including malaria prevention and treatment.
General Clark is one of the country's most distinguished retired military officers and a respected international voice in public affairs and diplomacy. He served as NATO Supreme Allied Commander from 1997 to 2000 and commanded troops in the campaign to end the Kosovo War, and he played a pivotal role in negotiating the Dayton Peace Accords to end the war in Bosnia.
"I am truly impressed by the private/public partnerships that Immtech has created as part of its effective business model to develop new treatments for global diseases," said General Clark. "I look forward to working closely with Immtech's leadership as the Company advances Immtech's promising drug pipeline."
General Clark served for 33 years with the United States Army, rising to the rank of 4-star general. He is a recipient of the Silver Star, Bronze Star, and Purple Heart, along with honorary Knighthoods from the British and Dutch governments. He was also made a commander of the French Legion of Honor, and in 2000 he was awarded the Presidential Medal of Freedom, the nation's highest civilian honor.
"We are honored to have General Clark join Immtech in this strategic advisory role," said Eric L. Sorkin, Immtech's Chairman and Chief Executive Officer. "General Clark will enhance Immtech's strategic work with international companies, foundations and governments. Few people have a better understanding of international cooperation, and we stand to benefit greatly from General Clark's expertise."
General Clark graduated top of his class from the United States Military Academy at West Point, and he holds a Master's Degree from Oxford University where he was a Rhodes Scholar. He was a U.S. presidential candidate in the 2004 election and is presently Chairman and CEO of Wesley K. Clark & Associates, a strategic advisory and consulting firm. He is also Chairman of Rodman and Renshaw, a New York based investment bank.
Immtech's first oral drug candidate, pafuramidine maleate, is currently in two phase II clinical trials for treatment and prevention of malaria. Each year malaria kills over one million people. It is also a significant threat to 125 million people who travel annually from developed countries to malaria endemic areas. Pafuramidine is also in two pivotal Phase III trials targeting the treatment of Pneumocystis pneumonia (PCP), a severe form of fungal infection in the lungs, and African sleeping sickness.
About Immtech Pharmaceuticals, Inc.
Immtech Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat infectious diseases. Immtech has advanced clinical programs that include new treatments for Pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (African sleeping sickness), and a well defined, expanding library of compounds targeting Hepatitis C, fungal infections, and bacterial infections. Immtech holds exclusive worldwide licenses to certain patents, patent applications and technology for products derived from a proprietary pharmaceutical platform. For additional information, please go to http://www.immtechpharma.com.
JAV
Another pretty huge advantage is the fact that Dyloject is stable at room temperature and does not require the intermediate step of pharmacy mixing before administration.
Intravenous infusions of Voltarol have to be freshly made up and used immediately. Once prepared, the infusion should not be stored.
In practice, what happens with these kinds of drugs is the pharmacy makes up N bags in the morning based on anticipated usage. Those that are not used are tossed at the end of the day. So you've just wasted the pharmacy time and the drug if it's not used.
Plus would you rather take the very expensive bed time and personnel cost to infuse, or would you rather administer the drug in a quick 30-second bolus?
If you were a hospital administrator, would you rather have a drug that needs to be mixed by the pharmacy and tossed at the end of the day, or would you rather just pop 20 vials of Dyloject in the Pyxis and forget about them until they're needed?
It's pretty clear that Voltarol is a dead duck when Dyloject is approved. It's also clear that a premium can be demanded for this drug--probably even more than they're anticipating.
>One would think a superior product on both safety and efficacy endpoints woudl capture even more than JAV's numbers, which are based on a 20-35% market share<
In the current environment, even more important is the ability to bolus dose. Pharmacoeconomic analyses indicate about a 50 pound stirling savings associated with bolus dosing over infusion. That's huge, and well worth the extra $7 (or about 3.50 stirling) per vial.
EIS
Anyone have a list of EISes?
I have BGF and CVP, and that's it in the US. Anything else?
Speaking of EGLE, did you listen to this conference:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=22595630
Another point is that there is a huge body of literature showing that NMDA receptor antagonists *prevent* progression to chronic pain in the first place.
From what I'm hearing, there will be significant profits to be made in Europe. The company has already announced plans to price Dyloject at a significant premium to the current agent. Pharmacoeconomic studies suggest ~50 pounds sterling savings compared with the competitor, which needs to be infused.
I don't expect a huge pop on European approval...as you say, the US market tends to treat this as a nonevent. However, I actually think JAV is underestimating the market at $75 million (predicated on taking half the market share from the infused product). Dyloject should take substantially more market share than that away from the inferior product. Extended infusion is cumbersome and costly.
I'm not hearing anyone getting too excited about European approval. IN ketamine is the reward here, and it's about as low-risk as you can get in biotech. US approval of Dyloject (which should be a shoe-in) is another reward.
Plus JAV remains substantially undervalued in comparison with competitors in the pain space.
I guess people would rather take flyers on DNDNs and MCUs than on low-risk, boring products.
Would be nice if JAV got back up to its 52-week highs, though.
Sure. Mark Joseph's or ? Just don't say Smith and Wollensky.
Sustained release OTC niacin. I get flushing even with 250 mg.
JAV
Anyone want to place a side bet on the week of approval for Dyloject? I'll take September 10 to 14.
JAV is performing well today, considering today's market disaster. Still way below where it should be.